Cameron Turtle
CIK: 0001758363
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (44 total)
- Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct600 shares at avg. $89.14$53K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct2.7K shares at avg. $90.10$242K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct2.6K shares at avg. $91.49$241K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct4K shares at avg. $92.31$368K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct5K shares at avg. $93.37$466K - Oct 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct100 shares at avg. $93.91$9K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct400 shares at avg. $89.07$36K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct3.7K shares at avg. $88.06$326K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct8.4K shares at avg. $87.15$732K - Sep 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct2.5K shares at avg. $86.36$216K - Aug 3, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct5.6K shares at avg. $95.93$541K - Aug 3, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct800 shares at avg. $93.97$75K - Aug 3, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct7.2K shares at avg. $95.10$681K - Aug 3, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct1.4K shares at avg. $96.82$135K - Aug 3, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct16 shares at avg. $97.46$2K - Jul 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct10.2K shares at avg. $87.44$890K - Jul 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct590 shares at avg. $88.91$52K - Jul 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct4.2K shares at avg. $88.12$373K - Jun 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct3.6K shares at avg. $69.40$247K - Jun 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct8.1K shares at avg. $70.50$575K - Jun 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct3.3K shares at avg. $71.38$235K - May 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct5.3K shares at avg. $69.54$369K - May 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct3.6K shares at avg. $70.77$255K - May 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct1K shares at avg. $71.76$72K - May 1, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Direct3.1K shares at avg. $73.14$227K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  SYRE Spyre Therapeutics, Inc. | Sale(S) | 600 | $89.14 | $53,484 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 2,683 | $90.10 | $241,738 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 2,638 | $91.49 | $241,351 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,989 | $92.31 | $368,225 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 4,990 | $93.37 | $465,916 | Direct |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 100 | $93.91 | $9,391 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 400 | $89.07 | $35,628 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,700 | $88.06 | $325,822 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 8,400 | $87.15 | $732,060 | Direct |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 2,500 | $86.36 | $215,900 | Direct |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 5,635 | $95.93 | $540,566 | Direct |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 800 | $93.97 | $75,176 | Direct |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 7,157 | $95.10 | $680,631 | Direct |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 1,392 | $96.82 | $134,773 | Direct |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 16 | $97.46 | $1,559 | Direct |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 10,176 | $87.44 | $889,789 | Direct |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 590 | $88.91 | $52,457 | Direct |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 4,234 | $88.12 | $373,100 | Direct |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,557 | $69.40 | $246,856 | Direct |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 8,149 | $70.50 | $574,505 | Direct |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,294 | $71.38 | $235,126 | Direct |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 5,300 | $69.54 | $368,562 | Direct |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,600 | $70.77 | $254,772 | Direct |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 1,000 | $71.76 | $71,760 | Direct |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 3,100 | $73.14 | $226,734 | Direct |
1-25 of 44 transactions
About Turtle Cameron
Turtle Cameron (SEC CIK 0001758363) files insider reports with the SEC as Chief Executive Officer of Spyre Therapeutics, Inc. (SYRE), Director of Damora Therapeutics, Inc. (DMRA) and Director of Oruka Therapeutics, Inc. (ORKA).
Signal8 holds 18 ownership filings by Turtle Cameron (2 Form 3, 16 Form 4), filed between Sep 6, 2024 and Oct 2, 2026. Those filings report 44 transactions, from Jan 15, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Turtle Cameron's filings is in WALTHAM, MA.
Recent filings by Turtle Cameron
- Oct 1, 2026: Open-market sales of SYRE shares (6 lines, Form 4, code S).
- Sep 1, 2026: Open-market sales of SYRE shares (4 lines, Form 4, code S).
- Aug 3, 2026: Open-market sales of SYRE shares (5 lines, Form 4, code S).
- Jul 1, 2026: Open-market sales of SYRE shares (3 lines, Form 4, code S).
- Jun 1, 2026: Open-market sales of SYRE shares (3 lines, Form 4, code S).
Other insiders filing for Spyre Therapeutics, Inc. (SYRE)
- King-Jones Heidy
- Burrows Scott L, Chief Financial Officer
- Albers Jeffrey W., Director
- Sloan Sheldon, Chief Medical Officer
- Fairmount Funds Management LLC, Director
- HENDERSON MICHAEL THOMAS, Director